Cantor Fitzgerald analyst Olivia Brayer raised the firm’s price target on United Therapeutics (UTHR) to $525 from $405 and keeps an Overweight rating on the shares. The firm likes the setup on the stock because idiopathic pulmonary fibrosis is now largely de-risked, the analyst tells investors in a research note. Cantor believes the stock should trade “with a 5-handle,” and that “it’s only a matter of months” before it does.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $575 from $510 at Oppenheimer
- United Therapeutics price target raised to $500 from $400 at H.C. Wainwright
- United Therapeutics price target raised to $560 from $415 at UBS
- Buy Rating for United Therapeutics: Promising TETON-2 Trial Results Highlight Tyvaso’s Potential in IPF Treatment
- United Therapeutics’ Tyvaso Shines in Phase III Trial, Poised for Growth in IPF Market